TMCnet News
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual MeetingSania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting LONDON, UK & NEW YORK, USA – 11 April 2024, Sania Therapeutics (the “Company”), focused on developing targeted genetic medicines for prevalent disorders today announces that it will be presenting three posters at the American Society of Gene & Cell Therapy 2024 Annual Meeting, taking place from 7-11 May 2024 in Baltimore, MD. Further details are below. Title: Generating human-evolved, cell-type-specific AAV capsids for targeted gene delivery Title: Titratable control of neuronal activity using precision genetic neuromodulation Title: A low dose, targeted, and controllable gene therapy for the treatment of spasticity Abstracts details will be shared in due course and the posters will be made available on Sania’s website following their presentation. About Sania Therapeutics Sania Therapeutics is a ground-breaking biotechnology company pioneering new approaches for targeted and controllable gene therapies to access prevalent disorders. Sania's approach harnesses neural circuits as a gateway to disease states. Their research and development is centred around a human-first approach to ultimately build more translatable, safer and cost-effective AAV gene therapies capable of treating millions of patients. Sania is based in London, UK. For more information visit www.saniarx.com.
|